Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 14/20 | 0.42 |
| ▸ | ADORA1 | P30542 | 14/20 | 0.42 |
| ▸ | ADORA2B | P29275 | 3/20 | 0.42 |
| ▸ | NPC1 | O15118 | 2/20 | 0.38 |
| ▸ | RAB9A | P51151 | 2/20 | 0.38 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.38 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.38 |
| ▸ | RELA | Q04206 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | BRD4 | O60885 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6133778 | 0.85 | ADORA2A (0.42) | ADORA2AADORA1ADORA2BNPC1RAB9A | |
| SCHEMBL6133623 | 0.81 | ADORA2A (0.42) | ADORA2AADORA1ADORA2BNPC1RAB9A | |
| SCHEMBL6133634 | 0.80 | ADORA2A (0.44) | ADORA2AADORA1ADORA2BBRD4ALDH1A1 | |
| SCHEMBL6135243 | 0.79 | ADORA2A (0.40) | ADORA2AADORA1ADORA2BBRD4ALDH1A1 | |
| SCHEMBL6134394 | 0.79 | ADORA2A (0.40) | ADORA2AADORA1ADORA2BBRD4ALDH1A1 | |
| SCHEMBL6133974 | 0.77 | CDK1 (0.44) | ADORA2AADORA1ADORA2BBRD4 | |
| SCHEMBL6133772 | 0.76 | ADORA2A (0.40) | ADORA2AADORA1ADORA2BNPC1RAB9A | |
| SCHEMBL6134659 | 0.76 | ADORA2A (0.39) | ADORA2AADORA1ADORA2BALDH1A1TP53 | |
| SCHEMBL6133555 | 0.75 | ADORA2A (0.41) | ADORA2AADORA1ADORA2BTP53 | |
| SCHEMBL6134113 | 0.74 | ADORA2A (0.43) | ADORA2AADORA1ADORA2BTP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050043315-A1 | Aminopyrimidine compounds, processes for their preparation and pharmaceutical compositions containing them | ASTELLAS PHARMA INC. (JP) | 2005-02-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050043315-A1 | Aminopyrimidine compounds, processes for their preparation and pharmaceutical compositions containing them | ADORA2B, ADORA2A, ADORA1 | ADORA2A 2/4885ADORA1 3/4885ADORA2B 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.